Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

Clinical Pharmacology and Therapeutics

Volumn 51, Issue 4, 1992, Pages 388-397

  Bertilsson, Leif ^a   Lou, Ya Qing ^b   Du, Yun Long ^b   Liu, Yin ^b   Kuang, Tang Yun ^b   Liao, Xia Mau ^b   Wang, Ke Yi ^b   Reviriego, Jesús ^b   Iselius, Lennart ^b   Sjöqvist, Folke ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE; MEPHENYTOIN;

ADULT; ARTICLE; CHIN; DRUG METABOLISM; ETHNIC DIFFERENCE; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE; SWEDEN;

CHINA; CHROMATOGRAPHY, GAS; DEBRISOQUIN; HUMANS; HYDROXYLATION; MEPHENYTOIN; PHENOTYPE; POLYMORPHISM, GENETIC; SWEDEN;

EID: 0026506140     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1038/clpt.1992.38     Document Type: Article

References (41)

1. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.
2. Sjöqvist F, Bertilsson L. Slow hydroxylation of tricyclic antidepressants - relationship to polymorphic drug oxidation. In: Kalow W, Goedde HW, Agarwal DP, eds. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R Liss, 1986:169-88.
3. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990;46:377-94.
4. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
5. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. CLIN PHARMACOL THER 1989;45:348-55.
6. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. CLIN PHARMACOL THER 1989;45:72-9.
7. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415-6.
8. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. CLIN PHARMACOL THER 1991;49:18-23.
9. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorhisms of debrisoquin and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
10. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;1:584-6.
11. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
12. Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. CLIN PHARMACOL THER 1985;38:394-401.
13. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
14. Drøhse A, Bathum L, Brøsen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989;27:620-5.
15. Kalow W, Goedde HW, Agarwal DP, eds. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R Liss, 1986.
16. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. CLIN PHARMACOL THER 1985; 38:402-8.
17. Lou YC, Ying L, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987;2:852-3.
18. Rudorfer MV, Lane EA, Chang WH, Zhang M, Potter WZ. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 17:433-40.
19. Potkin SG, Shen Y, Pardes H, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984;12:167-72.
20. Bertilsson L, Åberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983;15:388-90.
21. LLerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent of debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
22. Kumana CR, Lauder IJ, Chan M, Ko W, Liu HJ. Differences in diazepam pharmacokinetics in Chinese and white Caucasians - relation to body lipid stores. Eur J Clin Pharmacol 1987;32:211-5.
23. Zhang Y, Reviriego J, Lou YQ, Sjöqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. CLIN PHARMACOL THER 1990;48:496-502.
24. Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. CLIN PHARMACOL THER 1988;44:431-5.
25. Sanz EJ, Villén T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotype in a Swedish population determined after coadministration with debrisoquin. CLIN PHARMACOL THER 1989;45:495-9.
26. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxymetabolite in biologic fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977;133:161-8.
27. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. CLIN PHARMACOL THER 1984; 36:733-80.
28. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 1984;307:121-7.
29. MacLean CJ, Morton NE, Elston RC. Skewness in comingled distributions. Biometrics 1976;32:695-9.
30. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450 dbl gene (P450IID1) associated with genetically deficient metabolism of debrisoquin and other drugs. Proc Natl Acad Sci USA 1988;85:5240-3.
31. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
32. Dahl ML, Johansson I, Porsmyr-Palmertz M, Ingelman-Sundberg M, Sjöqvist, F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. CLIN PHARMACOL THER 1992;52:12-7.
33. Benitez J, LLerena A, Cobaleda J. Debrisoquin oxidation polymorphism in a Spanish population. CLIN PHARMACOL THER 1988;44:74-7.
34. Horai Y, Nakano M, Ishisaki T, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese. CLIN PHARMACOL THER 1989;46:198-207.
35. Xu XM, Jiang WD. Debrisoquine hydroxylation in a Chinese population. Chin J Physiol Sci 1989;5:361-6.
36. Yue QY, Bertilsson L, Dahl-Puustinen ML, et al. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 1989;2:870.
37. Johansson I, Yue QY, Dahl ML, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553-6.
38. Lou YC. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab Rev 1990;22:451-75.
39. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJJ. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. New Engl J Med 1989;320:565-70.
40. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991;12:102-7.
41. Meier UT, Dayer P, Malé PJ, Kronbach T, Meyer UA. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. CLIN PHARMACOL THER 1985;38:488-94.